Wolverine Trading, LLC Cardiff Oncology, Inc. Call Options Transaction History

Wolverine Trading, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$2.05 - $2.77 $41,410 - $55,954	-20,200 Reduced 56.42%	15,600 $41,000
Q2 2024 Aug 14, 2024	SELL	$2.22 - $5.89 $6,216 - $16,492	-2,800 Reduced 7.25%	35,800 $79,000
Q1 2024 May 15, 2024	BUY	$1.46 - $5.91 $56,356 - $228,126	38,600 New	38,600 $206,000
Q3 2023 Nov 15, 2023	BUY	$1.38 - $2.18 $20,010 - $31,610	14,500 New	14,500 $20,000
Q1 2022 May 16, 2022	SELL	$2.11 - $7.25 $22,788 - $78,300	-10,800 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$5.18 - $7.24 $55,944 - $78,192	10,800 New	10,800 $67,000
Q3 2021 Nov 12, 2021	SELL	$5.01 - $7.58 $75,150 - $113,700	-15,000 Closed	0 $0
Q2 2021 Aug 06, 2021	BUY	$6.65 - $10.04 $99,750 - $150,600	15,000 New	15,000 $108,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $109M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.